# Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions

> **NCT04184284** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 246 (actual)

## Conditions studied

- Asthma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04184284
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2023-12-19
- **Final completion:** 2023-12-19
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184284, "Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04184284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*